Anrikefon
Phase 3Small molecule
Anrikefon is one of 19 small molecule programs targeting Gallbladder Stones. It is currently in Phase 3.
3
Indications
4
Total Trials
4
Active Trials
18
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
23 competitors in Postoperative Analgesia
#DrugCompanyPhaseTrials
1Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Decadron
AAspen Global Incorporated
Approved
Duragesic
CCephalon
Approved
Nubain
AAultman Health Foundation
Approved
Celebrex
PPhiladelphia Eye Associates
Approved
EXPAREL
Pacira Pharmaceuticals, IncApproved
Intrathecal Morphine
Pacira Pharmaceuticals, IncPhase 3
Bupivacaine Only
Pacira Pharmaceuticals, IncPhase 3
Anrikefon
ZZhujiang Hospital
Phase 3
Fentanyl and Bupivacaine
HHospital Central Dr. Luis Ortega
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Postoperative Analgesia1 trial
Post Operative Pain1 trial
Pruritus Chronic1 trial
Gallbladder Stones1 trial
A Multicenter, Randomized, Parallel-Group Controlled Study Evaluating the Efficacy and Safety of Anrikefon in Postoperative Pain Management in Patients Undergoing Elective Laparoscopic Cholecystectomy Under General Anesthesia
Not yet recruiting·AAffiliated Hospital of Guangdong Medical University·Phase 2·NCT07741188·144 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Anrikefon. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- ZZhujiang Hospital